Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wedbush Reiterates Outperform on ARS Pharmaceuticals, Maintains $17 Price Target BENZINGA 8:34 AM ET May-18-2023 Wedbush analyst Andreas Argyrides reiterates ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and maintains $17 price target.